Scientists at Harvard take it daily. Initial human studies confirm what decades of animal research suggested. The longevity molecule, which the world's leading researchers have been studying for twenty years, is finally here. This is what science truly says about it.
The fountain of youth is a human obsession, as old as humanity itself. Every civilization, every era, every generation had its own version of it - the elixir, the spring, the ritual, the cure. Most of them turned out to be wishful thinking masquerading as a discovery. What is currently happening in longevity research is different. Not because science has found immortality. But because it has found something that shouldn't exist: a measurable, reversible biological mechanism of aging. And a molecule that targets it directly.
The molecule is NAD+. The intervention is NMN. And the scientists researching it are not on the fringes of their field. They are researching at Harvard, at Washington University School of Medicine, at the University of Tokyo. They publish in Science, in Nature, and in Cell Metabolism. And some of them take NMN themselves.
The molecule that changed how science thinks about aging
NAD+, short for Nicotinamide Adenine Dinucleotide, has been known to science for over a century. What has changed in the last two decades is the understanding of what its decline actually means. In 2013, a groundbreaking study from David Sinclair's lab at Harvard Medical School showed that elevating NAD+ levels in aging mice reversed vascular aging, improved mitochondrial function, and produced measurable improvements in muscle strength and endurance. The mice not only slowed their aging. They reversed its markers.
Then NAD+ research accelerated dramatically. Shin-ichiro Imai at Washington University School of Medicine developed a conceptual model called NAD World - the idea that NAD+ acts as a crucial systemic signaling molecule that maintains the biological robustness of the body's entire communication network.
His team's work over the following decade established NMN as the most direct and efficient precursor to NAD+, showing that oral supplementation can restore NAD+ levels in aging mammals with measurable, consistent results.
NMN could improve the metabolism of adult humans, making it more like that of a person ten or twenty years younger.
Dr. Shin-ichiro Imai, MD, PhD
The reason this is so important is what NAD+ actually does. It powers over 500 enzymatic reactions in the human body. It is needed for mitochondria to produce energy. It activates sirtuins, a family of proteins directly linked to longevity, regulation of inflammation, and DNA repair.
It regulates the internal clock. It is involved in the synthesis of sex hormones. It controls the metabolism of immune cells. When NAD+ declines - and it declines in every adult from their mid-twenties, reaching about half its peak value by middle age - all these systems simultaneously work less efficiently. The result is what most people simply call aging.
What twenty years of research have actually proven
Animal research on NAD+ and NMN is extensive and remarkably consistent. In mice, NMN supplementation has suppressed age-related weight gain, boosted energy metabolism, improved insulin sensitivity, restored skeletal muscle, enhanced eye function, protected the heart from damage, slowed cognitive decline in Alzheimer's models, and extended lifespan markers. The results from dozens of independent studies point in the same direction - with a consistency unusual for a biological intervention.
Human studies began appearing from 2020, and the data, though at an earlier stage than animal research, are promising. The most significant study to date examined 25 postmenopausal women in a randomized, placebo-controlled double-blind trial and found significant improvements in muscular insulin sensitivity after 10 weeks of daily NMN supplementation.
Another twelve-week study noted improvements in sleep quality and physical performance. A study on amateur runners showed that NMN significantly improved oxygen efficiency and aerobic capacity. NAD+ blood levels measurably increased in these studies within a few weeks of starting supplementation.
Clinically, some patients report more energy, better recovery, and sharper cognitive performance. Animal studies show promising longevity effects, but human studies are still in early stages.
Dr. Elliot Dinetz, MD
Why the scientists who research it take it themselves
In pharmaceutical research, it is uncommon for scientists to take their own experimental drugs. It happens when the evidence is compelling enough that waiting for decades of studies seems like an unnecessary delay.
David Sinclair, Harvard's most prominent longevity researcher, has publicly stated that he takes NMN daily. He said his lipid profile has dramatically improved, he feels more energetic, and his blood markers at almost 60 years old are closer to those of a 31-year-old. Shin-ichiro Imai's team at Washington University has expressed similar confidence in the direction of the research.
This is not a scientist recommending a supplement - it is the person leading the studies deciding that the precautionary principle works both ways: that the risk of not addressing NAD+ decline is higher than the risk of addressing it with the safest, best-researched intervention available.
His blood markers at almost 60 years old are closer to those of a 31-year-old.
-About David Sinclair, longevity researcher at Harvard Medical School, regarding his own NMN protocol
Why this means more for women than headlines suggest
Most debates about longevity revolve around aging in general. The specific effects on women are more urgent and far less frequently addressed. The decline of NAD+ in women does not happen in isolation. It occurs in parallel with hormonal changes - perimenopause can begin as early as 35, menopause occurs on average at 51-52 years old - and both processes reinforce each other in ways still underrepresented in research.
The enzyme responsible for producing progesterone requires NAD+ as a cofactor. This means that the hormonal symptoms of perimenopause - the brutal luteal phase, worsening PMS, mood swings, disturbed sleep patterns - are not purely hormonal in origin. They are also cellularly driven. Addressing NAD+ decline does not replace hormonal support where needed, but it addresses a dimension of women's hormonal health that has been almost entirely absent from clinical discussion until now.
Research into women's health receives less than 1% of the global medical research budget. The first human study on NMN specifically conducted on women appeared in 2021. There is a direct connection between these two facts.
So, has eternal youth actually been discovered?
No. And anyone who tells you otherwise is selling you something even more aggressively than we are. Aging is not a single mechanism, and NMN does not fully reverse it. What has been discovered is something more specific and arguably more useful: one of the primary biological drivers of aging, a molecule whose decline explains a remarkable proportion of what we experience as getting older, and a direct intervention that measurably restores it.
This is not immortality. But it is the most scientifically credible intervention in the field of aging currently available. The gap between "eternal youth" and "the best-evidenced biological intervention against age-related decline currently available" is large in mythology and small in practical daily life for the woman who is 38 and exhausted in a way she cannot explain.
The bottom line
Eternal youth has not been discovered. What has been discovered is that aging has a biological mechanism, that this mechanism is linked to the decline of NAD+, and that NMN is the most direct, best-researched intervention to address it. For women in particular, the implications extend to hormonal health, sleep, recovery, cognitive performance, and metabolism - in ways that research is only just beginning to fully map.
Sources:
- Covarrubias, A. J., Perrone, R., Grozio, A., & Verdin, E. (2021). NAD+ metabolism and its roles in cellular processes during ageing. Nature Reviews Molecular Cell Biology, 22(2), 119–141. https://doi.org/10.1038/s41580-020-00313-x
- Grozio, A., Mills, K. F., Yoshino, J., et al. (2019). Slc12a8 is a nicotinamide mononucleotide transporter. Nature Metabolism, 1(1), 47–57. https://doi.org/10.1038/s42255-018-0009-4
- Imai, S. I., & Guarente, L. (2014). NAD+ and sirtuins in aging and disease. Trends in Cell Biology, 24(8), 464–471. https://doi.org/10.1016/j.tcb.2014.04.002
- Kim, M., Seol, J., Sato, T., et al. (2022). Effect of 12-week intake of NMN on sleep quality, fatigue, and physical performance. Nutrients, 14(4), 755. https://doi.org/10.3390/nu14040755
- Liao, B., Zhao, Y., Wang, D., et al. (2021). NMN supplementation enhances aerobic capacity in amateur runners. JISSN, 18(1), 54. https://doi.org/10.1186/s12970-021-00442-4
- Massudi, H., Grant, R., Braidy, N., et al. (2012). Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLOS ONE, 7(7), e42357. https://doi.org/10.1371/journal.pone.0042357
- Mills, K. F., Yoshida, S., Stein, L. R., et al. (2016). Long-term administration of NMN mitigates age-associated physiological decline in mice. Cell Metabolism, 24(6), 795–806. https://doi.org/10.1016/j.cmet.2016.09.013
- Shade, C. (2020). The science behind NMN: A stable, reliable NAD+ activator. Integrative Medicine, 19(1), 12–14.
- Yoshino, M., Yoshino, J., Kayser, B. D., et al. (2021). Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science, 372(6547), 1224–1229. https://doi.org/10.1126/science.abe9985